^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Trazimera (trastuzumab-qyyp) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
Published date:
02/08/2022
Excerpt:
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer...Randomized patients received intravenous PF-05280014 or trastuzumab-EU, each plus paclitaxel, until objective disease progression. OS...The estimated survival rates (95% CI) at 1 year were 89.4% (85.6–92.2) for the PF-05280014 group and 87.5% (83.5–90.6) for the trastuzumab-EU group.
Secondary therapy:
paclitaxel
DOI:
10.1007/s40259-021-00513-7
Trial ID:
Source:
Title:
Abstract P1-18-08: Trazimera (a trastuzumab biosimilar) in HER2-positive metastatic breast cancer: Long-term safety and overall survival data
Excerpt:
Eligible patients were randomized 1:1 to receive intravenous Trazimera or Herceptin-EU, each plus paclitaxel....Estimated 2-year survival rates were 82.26% for Trazimera and 77.50% for Herceptin-EU; corresponding estimated 3-year rates were 77.17% and 75.33%....These results represent the longest known follow-up data reported for a trastuzumab biosimilar study in patients with HER2-positive MBC.
Secondary therapy:
paclitaxel
DOI:
10.1158/1538-7445.SABCS19-P1-18-08
Trial ID:
Evidence Level:
Sensitive: C1 - Off-label
(Approved for Gastroesophageal Junction Adenocarcinoma)
New
Excerpt:
Trazimera in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
